Research study · PLOS One · 2026
Investigating the effects of cannabinoids for the reduction of inflammation and sickle cell disease pain (CRISP); A protocol for a randomized double-blind placebo-controlled study
Verified on PubMed Oxford CEBM Level 1B: Randomized Controlled Trial
A 2026 randomized controlled trial in PLOS One tested cannabinoids in inflammation. No results are available yet, because this is only the plan for the study. This paper establishes that a carefully designed trial of a prescription cannabis-type medicine for pain in sickle cell disease is underway, and it shows what the researchers plan to.
In plain language
Study overview
This is a plan for a study of adults with sickle cell disease who have long-lasting pain. Participants are randomly assigned to take a prescription synthetic form of the main active ingredient in cannabis (called dronabinol) or an inactive pill for eight weeks, and neither they nor the researchers know which one they receive.
Findings
No results are available yet, because this is only the plan for the study. The researchers describe what they will measure, including pain, quality of life, mood, thinking ability, body inflammation, and side effects.
Explore Dr. Caplan's interactive tool detailing cytochrome P450 pathways, clinical titration intervals, and physician surveillance rules.
The deeper readScientific analysis
Sickle Cell Disease (SCD) is a hemoglobinopathy affecting millions of people globally. Pain, both acute and chronic, affects over half of those living with SCD, but treatment of chronic pain is an ongoing challenge. While opioid treatments are widely used for chronic pain, its efficacy is limited, so alternatives must be explored. This protocol outlines a procedure for investigation of dronabinol, an FDA-approved synthetic tetrahydrocannabinol (THC), for the treatment of pain in patients living with SCD and chronic pain. The study is an 8-week, randomized, double-blind placebo-controlled study which aims to assess both the efficacy and safety of this opioid alternative to pain treatment. The study will also track biomarkers of inflammation as THC has demonstrated anti-inflammatory properties, and inflammation is a driver of SCD pain and disease severity. Results from this study have the potential to further clinical understanding of cannabinoids for pain management in Sickle Cell Disease treatment and spark new questions for research.
The paper
Citation
Bellis J, Monk L, Jhawar R, Pollock G, Liu A, Jacobs-McFarlane C, et al. Investigating the effects of cannabinoids for the reduction of inflammation and sickle cell disease pain (CRISP); A protocol for a randomized double-blind placebo-controlled study. PLOS One (2026). PubMed 41604381 · DOI
Limitations the authors noted
Small, short (8 weeks), single-center study. Blinding may be compromised because higher THC doses are psychoactive. Does not examine effects on pain crisis severity or frequency. Long-term effects not addressed. Exclusion of daily cannabis users limits generalizability.
In practice
Why this matters
This paper establishes that a carefully designed trial of a prescription cannabis-type medicine for pain in sickle cell disease is underway, and it shows what the researchers plan to measure. It does not show that the medicine works or is safe, since no outcomes have been reported. Readers should treat it as a sign of where the research is heading, and wait for the final results before drawing any conclusions about pain relief.
Frequently asked questions
Clinical Questions & Answers
What were the primary clinical findings regarding Cannabinoids and Chronic pain?
No results are available yet, because this is only the plan for the study. The researchers describe what they will measure, including pain, quality of life, mood, thinking ability, body inflammation, and side effects.
What study limitations or clinical safeguards should patients keep in mind?
Small, short (8 weeks), single-center study. Blinding may be compromised because higher THC doses are psychoactive. Does not examine effects on pain crisis severity or frequency.
Browse related research
Condition: Chronic pain Condition: Inflammation Condition: Sickle cell anemia Topic: Cannabinoids Topic: THC
Related on CED Clinic
Back to Daily Research and Patient Questions
Reviewed by Dr. Caplan on October 19, 2026.
This page is general education about a published study. It is not medical advice and does not create a doctor-patient relationship. For care specific to you, book a consultation.
